As of 2025-07-09, the Intrinsic Value of Relmada Therapeutics Inc (RLMD) is -11.41 USD. This RLMD valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.61 USD, the upside of Relmada Therapeutics Inc is -1,969.47%.
Based on its market price of 0.61 USD and our intrinsic valuation, Relmada Therapeutics Inc (RLMD) is overvalued by 1,969.47%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -11.41 - -11.41 | -11.41 | -1,969.47% |
| P/E | (44.21) - (41.93) | (43.91) | -7297.5% |
| DDM - Stable | (17.38) - (46.88) | (32.13) | -5366.1% |
| DDM - Multi | (16.02) - (34.21) | (21.89) | -3687.3% |
| Market Cap (mil) | 20.25 |
| Beta | 2.18 |
| Outstanding shares (mil) | 33.19 |
| Enterprise Value (mil) | 19.10 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.78% |
| Cost of Debt | 5.00% |
| WACC | 7.23% |